Evidence map›Paper›PMID 39677813›Full record

ArticlebioRxiv : the preprint server for biology2024

A robust benchmark for detecting low-frequency variants in the HG002 Genome In A Bottle NIST reference material.

Camille A Daniels, Adetola Abdulkadir, Megan H Cleveland, Jennifer H McDaniel, David Jáspez, Luis Alberto Rubio-Rodríguez, Adrián Muñoz-Barrera, José Miguel Lorenzo-Salazar, Carlos Flores, Byunggil Yoo and 28 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Camille A DanielsMedical Device Innovation Consortium (MDIC), 1655 N Ft. Myer Drive, 12th Floor, Arlington, VA, USA 22209.ORCID 0000-0002-5227-5394
Adetola AbdulkadirMedical Device Innovation Consortium (MDIC), 1655 N Ft. Myer Drive, 12th Floor, Arlington, VA, USA 22209.ORCID 0009-0007-1195-1900
Megan H ClevelandMaterial Measurement Laboratory, National Institute of Standards and Technology (NIST), 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA.ORCID 0000-0002-5584-9314
Jennifer H McDanielMaterial Measurement Laboratory, National Institute of Standards and Technology (NIST), 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA.ORCID 0000-0003-1987-0914
David JáspezGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Polígono Industrial de Granadilla s/n, 38600 Santa Cruz de Tenerife, Spain.ORCID 0000-0001-7923-0068
Luis Alberto Rubio-RodríguezGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Polígono Industrial de Granadilla s/n, 38600 Santa Cruz de Tenerife, Spain.ORCID 0000-0002-4566-1203
Adrián Muñoz-BarreraGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Polígono Industrial de Granadilla s/n, 38600 Santa Cruz de Tenerife, Spain.
José Miguel Lorenzo-SalazarGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Polígono Industrial de Granadilla s/n, 38600 Santa Cruz de Tenerife, Spain.ORCID 0000-0002-5135-2861
Carlos FloresGenomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Polígono Industrial de Granadilla s/n, 38600 Santa Cruz de Tenerife, Spain.ORCID 0000-0001-5352-069X
Byunggil YooGenomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO, USA.
Sayed Mohammad Ebrahim SahraeianRoche Sequencing Solutions, Santa Clara, CA, 95050, USA.
Yina WangIllumina Inc., San Diego, CA, USA.ORCID 0009-0000-6217-5031
Massimiliano RossiIllumina Inc., San Diego, CA, USA.ORCID 0000-0002-3012-1394
Arun VisvanathIllumina Inc., San Diego, CA, USA.ORCID 0009-0000-9089-9184
Lisa MurrayIllumina Inc., San Diego, CA, USA.
Wei-Ting ChenIllumina Inc., San Diego, CA, USA.ORCID 0009-0003-9928-0945
Severine CatreuxIllumina Inc., San Diego, CA, USA.ORCID 0009-0008-1813-1240
James HanIllumina Inc., San Diego, CA, USA.ORCID 0009-0002-0333-7568
Rami MehioIllumina Inc., San Diego, CA, USA.ORCID 0009-0003-6908-103X
Gavin ParnabyIllumina Inc., San Diego, CA, USA.ORCID 0009-0006-7432-8246
Andrew CarrollGoogle Inc, Mountain View, CA, USA.ORCID 0000-0002-4824-6689
Pi-Chuan ChangGoogle Inc, Mountain View, CA, USA.ORCID 0000-0003-3021-6446
Kishwar ShafinGoogle Inc, Mountain View, CA, USA.ORCID 0000-0001-5252-3434
Daniel CookGoogle Inc, Mountain View, CA, USA.ORCID 0000-0003-3347-562X
Alexey KolesnikovGoogle Inc, Mountain View, CA, USA.
Lucas BrambrinkGoogle Inc, Mountain View, CA, USA.
Mohammed Faizal Eeman MootorDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-4154-455X
Yash PatelDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-3113-7010
Takafumi N YamaguchiDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1082-3871
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-0553-7520
Karolina SienkiewiczDepartment of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Jonathan FooxDepartment of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Christopher E MasonDepartment of Medicine and Weill Cornell Cancer Center, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-1850-1642
Bryan R LajoieElement Biosciences, San Diego, CA, USA.ORCID 0000-0002-1895-8896
Carlos A Ruiz-PerezElement Biosciences, San Diego, CA, USA.ORCID 0000-0001-7275-3923
Semyon KruglyakElement Biosciences, San Diego, CA, USA.ORCID 0000-0002-8353-1506
Justin M ZookMaterial Measurement Laboratory, National Institute of Standards and Technology (NIST), 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA.ORCID 0000-0003-2309-8402
Nathan D OlsonMaterial Measurement Laboratory, National Institute of Standards and Technology (NIST), 100 Bureau Dr, MS8312, Gaithersburg, MD 20899, USA.ORCID 0000-0003-2585-3037

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
VAST Center: Viromes Across Space(s) and TimeU54AG089334 · NIA · STANFORD UNIVERSITY · PI Christopher Edward Mason · 2025 to 2026
$13.3M
Tool Core- BoutrosU54HG012517 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, PING, PEIPEI · 2022 to 2025
$10.6M
Advancing method benchmarking and data sharing through crowd-sourced competitions in cancer researchU24CA248265 · NCI · SAGE BIONETWORKS · PI BOUTROS, PAUL CHRISTOPHER, VARMA, SUSHEEL · 2020 to 2024
$4.1M
The Epitranscriptome as a Novel Mechanism of Arsenic-Induced Diabetes.R01ES032638 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KUPSCO, ALLISON, MASON, CHRISTOPHER EDWARD · 2021 to 2025
$3.9M
Virginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · NCI · OLD DOMINION UNIVERSITY · PI OLIVER John SEMMES · 2022 to 2026
$3.2M
NCI NIH HHS P30 CA016042NCI NIH HHS U24 CA248265NCI NIH HHS U2C CA271894NHGRI NIH HHS U54 HG012517NIA NIH HHS U54 AG089334NIEHS NIH HHS R01 ES032638
6 · The paper itself

Abstract

Somatic mosaicism is an important cause of disease, but mosaic and somatic variants are often challenging to detect because they exist in only a fraction of cells. To address the need for benchmarking subclonal variants in normal cell populations, we developed a benchmark containing mosaic variants in the Genome in a Bottle Consortium (GIAB) HG002 reference material DNA from a large batch of a normal lymphoblastoid cell line. First, we used a somatic variant caller with high coverage (300x) Illumina whole genome sequencing data from the Ashkenazi Jewish trio to detect variants in HG002 not detected in at least 5% of cells from the combined parental data. These candidate mosaic variants were subsequently evaluated using >100x BGI, Element, and PacBio HiFi data. High confidence candidate SNVs with variant allele fractions above 5% were included in the HG002 draft mosaic variant benchmark, with 13/85 occurring in medically relevant gene regions. We also delineated a 2.45 Gbp subset of the previously defined germline autosomal benchmark regions for HG002 in which no additional mosaic variants >2% exist, enabling robust assessment of false positives. The variant allele fraction of some mosaic variants is different between batches of cells, so using data from the homogeneous batch of reference material DNA is critical for benchmarking these variants. External validation of this mosaic benchmark showed it can be used to reliably identify both false negatives and false positives for a variety of technologies and detection algorithms, demonstrating its utility for optimization and validation. By adding our characterization of mosaic variants in this widely-used cell line, we support extensive benchmarking efforts using it in simulation, spike-in, and mixture studies.

Indexed as

benchmarkinggenome in a bottlegenome sequencingmosaic variantSNVSomatic mosaicismsomatic variantvariant calling

Identifiers

PMID39677813
PMCPMC11642750

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.